GSK’s fully liquid presentation of its meningococcal vaccine Menveo has been approved by the European Commission (EC) to protect individuals aged two years and older against invasive meningococcal disease (IMD). The single-vial presentation is designed to simplify the vaccination process by offering healthcare providers an option that does not require reconstitution before use. Source: PM Live 29/11/2024